Cargando…

Anti-cytokine therapy in fibrosing alveolitis: where are we now?

Idiopathic pulmonary fibrosis (IPF) is a condition that has a poor prognosis, with a median survival of 4-5 years irrespective of treatment. Ziesche et al (N Engl J Med 1999, 341: 1264-1269) describe an open randomised trial of 18 patients with IPF, unresponsive to corticosteroid treatment at high d...

Descripción completa

Detalles Bibliográficos
Autor principal:	Millar, Ann
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2000
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59532/ https://www.ncbi.nlm.nih.gov/pubmed/11667955 http://dx.doi.org/10.1186/rr2

Ejemplares similares

Autoantibodies in cryptogenic fibrosing alveolitis
por: Singh, Suveer, et al.
Publicado: (2001)

AI in medicine: Where are we now and where are we going?
por: Shandhi, Md Mobashir Hasan, et al.
Publicado: (2022)

Ventilator-associated tracheobronchitis: where are we now?
por: Nseir, Saad, et al.
Publicado: (2014)

Genetic counseling globally: Where are we now?
por: Ormond, Kelly E., et al.
Publicado: (2018)

Fibrosing Alveolitis in Hematologic Malignancy Patients Undergoing Hematopoietic Cell Transplantation
por: Salman, Huda, et al.
Publicado: (2010)

Neoadjuvant treatment of rectal cancer: where are we now?
por: Kalyan, Aparna, et al.
Publicado: (2016)

COVID-19 – Where should we go now?
por: Allen, Claire, et al.
Publicado: (2020)

Conduction System Pacing: Where Are We Now?
por: Niazi, Imran
Publicado: (2022)

Tumour necrosis factor-α production in fibrosing alveolitis is macrophage subset specific
por: Pantelidis, Panos, et al.
Publicado: (2001)

Medically Complex Living Kidney Donors: Where Are We Now?
por: Textor, Stephen C.
Publicado: (2019)

Polygenic risk scores for complex diseases: where are we now?
por: Loh, Marie, et al.
Publicado: (2023)

Mechanical Thrombectomy- Where Do We Stand Now ?
por: Chakraborty, Debabrata, et al.
Publicado: (2022)

Mobile Phones, Brain Tumors, and the Interphone Study: Where Are We Now?
por: Swerdlow, Anthony J., et al.
Publicado: (2011)

Private specificities can dominate the humoral response to self-antigens in patients with cryptogenic fibrosing alveolitis
por: Robinson, Cleo, et al.
Publicado: (2001)

Social radiology: Where to now?
por: Ho, ELM
Publicado: (2012)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

World Health Organization AWaRe framework for antibiotic stewardship: Where are we now and where do we need to go? An expert viewpoint
por: Mudenda, Steward, et al.
Publicado: (2023)

Targeting therapy in pemphigus: Where are we now and where are we going?
por: Abulikemu, Kailibinuer, et al.
Publicado: (2023)

CAR-T cell therapy: Where are we now, and where are we heading?
por: Wang, Jia-Yi, et al.
Publicado: (2023)

Where are we now?
Publicado: (1977)

Aging with Down Syndrome—Where Are We Now and Where Are We Going?
por: Alldred, Melissa J., et al.
Publicado: (2021)

5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
por: Hamilton, Robert J, et al.
Publicado: (2011)

Extension for Community Healthcare Outcomes (ECHO) Telementoring in the Military: Where We Are Now, Opportunities and Challenges
por: Katzman, Joanna, et al.
Publicado: (2021)

Alveolitis
por: Morales Piñan, Margarita
Publicado: (1988)

Alveolitis
por: Montes Fernández, Dulce María
Publicado: (1995)

NIPPV: Where Are We Now?
por: Fakharian, Atefeh, et al.
Publicado: (2013)

Onchodermatitis: Where Are We Now?
por: Murdoch, Michele E.
Publicado: (2018)

Venoms as an adjunctive therapy for Parkinson’s disease: where are we now and where are we going?
por: Gazerani, Parisa
Publicado: (2020)

Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
por: Wasilewicz, Michał P., et al.
Publicado: (2023)

Anticytokine therapy for periodontal diseases: Where are we now?
por: Waykole, Yogesh Prakash, et al.
Publicado: (2009)

Hotoda’s Sequence and Anti-HIV Activity: Where Are We Now?
por: Romanucci, Valeria, et al.
Publicado: (2019)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

Platelet-Rich Plasma: Where Are We Now and Where Are We Going?
por: Cole, Brian J., et al.
Publicado: (2010)

Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021)

Ten Years for GHSP: Where Are We Now? Where Will We Go?
por: Bhutta, Zulfiqar A., et al.
Publicado: (2023)

Aromatase inhibitors--where are we now?
por: Miller, W. R.
Publicado: (1996)

Depression research: where are we now?
por: Lee, Saebom, et al.
Publicado: (2010)

Personal genomics: Where are we now?
por: Angrist, Misha
Publicado: (2016)

9. GFR - Where are We Now?
por: Delanghe, Joris R.
Publicado: (2009)

Calcaneal fractures: Where are we now?
por: Razik, Aisha, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_54uavs4e7jf9m83k5s6ck5l8ac